Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number

.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly

.

\*\* Signature of Reporting Person

Date

/s/ Ujwala Mahatme

01/05/2022

Remarks:

4. The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $54,000.

31, 2022.

3. The option was issued on January 3, 2022. The shares underlying the option are scheduled to vest in four equal quarterly installments, on March 31, 2022, June 30, 2022, September 30, 2022, and December

2. Not applicable.

2022.

1. The option was granted on January 3, 2022. The shares underlying the option are scheduled to vest in equal quarterly installments, on March 31, 2022, June 30, 2022, September 30, 2022, and December 31,

Explanation of Responses:

buy)

(right to

Stock

$2.82

01/03/2022

A

47,872

(3)

01/03/2032

47,872 $1.13(4)

72,872

D

Option

Common

Stock

buy)

(right to

Stock

$2.82

01/03/2022

A

25,000

(1)

01/03/2032

25,000

(2)

25,000

D

Option

Common

Stock

Code

V

(A)

(D)

Exercisable

Date

Title

Shares

Date

Expiration

of

Number

or

Amount

3, 4 and 5)

(Instr. 4)

of (D) (Instr.

Transaction(s)

Disposed

Reported

Security

(A) or

Following

(I) (Instr. 4)

Derivative

Acquired

(Instr. 3 and 4)

Owned

or Indirect

(Instr. 4)

(Instr. 3)

Price of

(Month/Day/Year)

8)

Securities

Derivative Security

(Instr. 5)

Beneficially

Direct (D)

Ownership

Security

or Exercise

(Month/Day/Year)

if any

Code (Instr.

Derivative

(Month/Day/Year)

Underlying

Security

Securities

Form:

Beneficial

Derivative

Conversion

Date

Execution Date,

Transaction

of

Expiration Date

of Securities

Derivative

derivative

Ownership

of Indirect

1. Title of

2.

3. Transaction

3A. Deemed

4.

5. Number

6. Date Exercisable and

7. Title and Amount

8. Price of

9. Number of

10.

11. Nature

(e.g., puts, calls, warrants, options, convertible securities)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(D)

(Instr. 3 and 4)

Code

V

Amount

Price

(A) or

Transaction(s)

Reported

(Instr. 4)

(Month/Day/Year)

8)

Owned Following

(I) (Instr. 4)

Ownership

(Month/Day/Year)

if any

Code (Instr.

5)

Beneficially

(D) or Indirect

Beneficial

Date

Execution Date,

Transaction

Disposed Of (D) (Instr. 3, 4 and

Securities

Form: Direct

of Indirect

1. Title of Security (Instr. 3)

2. Transaction

2A. Deemed

3.

4. Securities Acquired (A) or

5. Amount of

6. Ownership

7. Nature

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

(City)

(State)

(Zip)

Person

Form filed by More than One Reporting

CAMBRIDGE

MA

02142

(Street)

X

Form filed by One Reporting Person

Line)

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable

ONE BROADWAY, 14TH FLOOR

C/O SUMMIT THERAPEUTICS INC.

01/03/2022

(Last)

(First)

(Middle)

3. Date of Earliest Transaction (Month/Day/Year)

below)

below)

Officer (give title

Other (specify

X

Director

10% Owner

Mahatme Ujwala

Summit Therapeutics Inc. [ SMMT ]

(Check all applicable)

1. Name and Address of Reporting Person

\*

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

or Section 30(h) of the Investment Company Act of 1940

Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

obligations may continue. See

Section 16. Form 4 or Form 5

hours per response:

0.5

Check this box if no longer subject to

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Estimated average burden

OMB Number:

3235-0287

Washington, D.C. 20549

OMB APPROVAL

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

SEC Form 4